ReviewTranslational research : the journal of laboratory and clinical medicine2013
Arthritis gene therapy and its tortuous path into the clinic.
Review in Translational research : the journal of laboratory and clinical medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 78 citations in OpenAlex.
- The evolving landscape of minimally invasive procedures in musculoskeletal diseases-part I.Frontiers in medicine · 2026Review
- Rethinking arthritis: exploring its types and emerging management strategies.Inflammopharmacology · 2025Review
- Production of Neutralizing Antibody.Methods in molecular biology (Clifton, N.J.) · 2024Article
- The Sheep as a Large Animal Model for the Investigation and Treatment of Human Disorders.Biology · 2022Review
- Targeting Human Osteoarthritic Chondrocytes with Ligand Directed Bacteriophage-Based Particles.Viruses · 2021Article
- Chondroprotection and Molecular Mechanism of Action of Phytonutraceuticals on Osteoarthritis.Molecules (Basel, Switzerland) · 2021Review
- Review
- Pathogenesis of Osteoarthritis: Risk Factors, Regulatory Pathways in Chondrocytes, and Experimental Models.Biology · 2020Review
- Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery.Journal of pharmacopuncture · 2019Review
- Editorial: Arthritis Gene Therapy Using Interleukin-1 Receptor Antagonist.Arthritis & rheumatology (Hoboken, N.J.) · 2018Article
- Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model.Human gene therapy. Clinical development · 2018Article
- Self-Complementary Adeno-Associated Virus-Mediated Interleukin-1 Receptor Antagonist Gene Delivery for the Treatment of Osteoarthritis: Test of Efficacy in an Equine Model.Human gene therapy. Clinical development · 2018Article
- Gene Delivery to Joints by Intra-Articular Injection.Human gene therapy · 2018Review
- P53-derived hybrid peptides induce apoptosis of synovial fibroblasts in the rheumatoid joint.Oncotarget · 2017Article
- Genome Engineering for Personalized Arthritis Therapeutics.Trends in molecular medicine · 2017Review
- PUMA gene delivery to synoviocytes reduces inflammation and degeneration of arthritic joints.Nature communications · 2017Article
- CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues.Arthritis & rheumatology (Hoboken, N.J.) · 2017Article
- Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- The gene therapy of collagen-induced arthritis in rats by intramuscular administration of the plasmid encoding TNF-binding domain of variola virus CrmB protein.Doklady. Biochemistry and biophysics · 2016Article
- Treatment of osteoarthritis using a helper-dependent adenoviral vector retargeted to chondrocytes.Molecular therapy. Methods & clinical development · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Arthritis is a disease of joints. The biology of joints makes them very difficult targets for drug delivery in a manner that is specific and selective. This is especially true for proteinaceous drugs ("biologics"). Gene transfer is the only technology that can solve the delivery problem in a clinically reasonable fashion. There is an abundance of preclinical data confirming that genes can be efficiently transferred to tissues within joints by intra-articular injection using a variety of different vectors in conjunction with ex vivo and in vivo strategies. Using the appropriate gene transfer technologies, long-term, intra-articular expression of anti-arthritic transgenes at therapeutic concentrations can be achieved. Numerous studies confirm that gene therapy is effective in treating experimental models of rheumatoid arthritis (RA) and osteoarthritis (OA) in the laboratory. A limited number of clinical trials have been completed, which confirm safety and feasibility but only 3 protocols have reached phase II; as yet, there is no unambiguous evidence of efficacy in human disease. Only 2 clinical trials are presently underway, both phase II studies using allogeneic chondrocytes expressing transforming growth factor-β1 for the treatment of OA. Phase I studies using adeno-associated virus to deliver interleukin-1Ra in OA and interferon-β in RA are going through the regulatory process. It is to be hoped that the recent successes in treating rare, Mendelian diseases by gene therapy will lead to accelerated development of genetic treatments for common, non-Mendelian diseases, such as arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.